Eli Lilly and Company $LLY Shares Bought by JLB & Associates Inc.

JLB & Associates Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,290 shares of the company’s stock after buying an additional 494 shares during the period. JLB & Associates Inc.’s holdings in Eli Lilly and Company were worth $8,614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in LLY. Sumitomo Mitsui Financial Group Inc. purchased a new stake in Eli Lilly and Company in the second quarter valued at $27,000. Evolution Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $29,000. Steph & Co. increased its position in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Financial Gravity Companies Inc. purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at about $31,000. Finally, Bare Financial Services Inc lifted its position in Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA granted Breakthrough Therapy designation for Lilly’s ovarian cancer candidate (sofetabart/mipitecan), improving the odds of faster development and a premium approval pathway for a novel oncology asset. Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug
• Positive Sentiment: Lilly launched a Phase 3b dosing study for retatrutide (obesity candidate), a near-term program de?risk step that could support label expansion and broaden commercial use if results are favorable. Eli Lilly Advances Retatrutide With New Phase 3b Obesity Dosing Study
• Positive Sentiment: Data/real?world studies continue to support obesity and metabolic franchises: SURMOUNT?REAL UK (tirzepatide real?world) updates and a retatrutide osteoarthritis signal suggest incremental clinical and commercial benefits beyond weight loss. These help underpin revenue upside for GLP/GIP drugs. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Lilly expanded its oncology imaging footprint with a new Phase 1 PET tracer study, signaling diversification into diagnostics/precision oncology that can boost long?term margins and pipeline value. Eli Lilly Expands Oncology Imaging Footprint With New Phase 1 PET Tracer Study
• Positive Sentiment: Executives at the JPMorgan Healthcare Conference reiterated that the obesity market will evolve to include more pill options, combos and better access — a structural message that supports multi?year demand growth for Lilly’s metabolic portfolio. What obesity drugmakers see next in the market: More pills, easier access and drug combinations
• Neutral Sentiment: Lilly confirmed its fourth?quarter 2025 earnings release and conference call for Feb. 4 — a scheduled event that will likely drive near?term volatility as investors re?assess guidance and sales cadence. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Organizational update: Lilly appointed Pranav Shroff as director of marketing — a routine personnel move with limited near?term financial impact but relevant for commercial execution. Eli Lilly appoints Pranav Shroff as director of marketing
• Negative Sentiment: Competition risk in key international markets: Sun Pharma won approval for a Wegovy generic in India, intensifying price and market?share pressure in a top growth region and foreshadowing similar generic/biologic competition scenarios. Eli Lilly, Novo Nordisk Set for Fierce Battle in India’s Obesity Drug Market as Sun Pharma Wins Wegovy Generic Nod
• Negative Sentiment: Legal/political overhang: coverage cites a lawsuit and public scrutiny over insulin pricing that can bring reputational and financial risk if litigation expands or results in penalties. Rokita Discusses Lawsuit Against Eli Lilly & Insulin Prices

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,087.63 on Friday. The firm has a 50 day moving average of $1,056.39 and a two-hundred day moving average of $878.04. The stock has a market capitalization of $1.03 trillion, a PE ratio of 53.21, a P/E/G ratio of 0.81 and a beta of 0.35. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue was up 53.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on LLY. National Bankshares set a $1,286.00 price target on shares of Eli Lilly and Company in a research report on Monday, December 1st. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Bank of America cut their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research report on Monday, December 15th. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday, November 10th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $1,174.61.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.